E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
Lan, Wenjun, Bian, Benjamin, Xia, Yi, Dou, Samir, Gayet, Odile, Bigonnet, Martin, Santofimia-Castaño, Patricia, Cong, Mei, Peng, Ling, Dusetti, Nelson, Iovanna, JuanVolume:
8
Language:
english
Journal:
Scientific Reports
DOI:
10.1038/s41598-018-26613-z
Date:
December, 2018
File:
PDF, 2.07 MB
english, 2018